PharmaShots | Incisive News in 3 Shots

Subscribe Now

Chronic Plaque Psoriasis

Boehringer Ingelheim Reports Results of Cyltezo (biosimilar- adalimumab) in P-III VOLTAIRE-X Study for Moderate-to-Severe Chronic Plaque Psoriasis

Boehringer Ingelheim Reports Results of Cyltezo (biosimilar- adalimumab) in P-III VOLTAIRE-X Study for Moderate-to-Severe Chronic...

April 23, 2021

Alvotech Reports the US FDA and EMA's Acceptance of AVT02 Proposed Biosimilar to Humira (adalimumab)

Alvotech Reports the US FDA and EMA's Acceptance of AVT02 Proposed Biosimilar to Humira (adalimumab)

November 20, 2020

UCB Reports Results of Bimekizumab in P-III BE VIVID Study to Treat Moderate to Severe Chronic Plaque Psoriasis

UCB Reports Results of Bimekizumab in P-III BE VIVID Study to Treat Moderate to Severe Chronic Plaque Psoriasis

October 17, 2019

Almirall's Ilumetri Receives EU Approval for the Treatment of Moderate-To-Severe Chronic Plaque Psoriasis in Adults

Almirall's Ilumetri Receives EU Approval for the Treatment of Moderate-To-Severe Chronic Plaque Psoriasis in Adults

September 19, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us